Sorry, your browser is out of date. To view this page correctly, please install a modern browser (Microsoft Edge, Firefox or Google Chrome).
SAI - Detailed view
Please log in as a company employee using your Swiss-Rx-Login. For further information please see the FAQ.
VYNDAQEL Weichkaps 20 mg 30 Stk
Drug
Vyndaqel 20 mg, Weichkapseln
Behandlung der Transthyretin-Amyloidose bei erwachsenen Patienten mit Wildtyp- oder hereditärer Kardiomyopathie
01.99.0. – various
HAM – Human medicine
KAPWE – Capsule, soft
S – synthetic products for human use
B – Dispensed on prescription by a physician or veterinarian (B)
Z – approved
3/5/2020
3/4/2025
Dosage strength
Vyndaqel 20 mg, Weichkapseln
Behandlung der Transthyretin-Amyloidose bei erwachsenen Patienten mit Wildtyp- oder hereditärer Kardiomyopathie
01
Z – approved
Package
7680670830010
No information made available
A/R – Authorised / referenced
30 capsule(s)
001
Z – approved
Declaration
Component
20 mg tafamidisum megluminum
12.2 mg tafamidisum
12.2 mg tafamidisum
macrogolum 400
polysorbatum 80
sorbitani oleas
gelatina
glycerolum
sorbitolum liquidum partim deshydricum
max. 44 mg sorbitolum
E 172 (flavum)
E 171
macrogolum 400
propylenglycolum
polyvinylis acetas phtalas
E 120
E 133
polysorbatum 80
sorbitani oleas
gelatina
glycerolum
sorbitolum liquidum partim deshydricum
max. 44 mg sorbitolum
E 172 (flavum)
E 171
macrogolum 400
propylenglycolum
polyvinylis acetas phtalas
E 120
E 133
Authorisation holder
7601001010604
Pfizer AG
Schärenmoosstrasse 99
8052 Zürich (ZH)
Schärenmoosstrasse 99
8052 Zürich (ZH)
Date of revision of the text
4/10/2024
Please log in as a company employee using your Swiss-Rx-Login. For further information please see the FAQ.
Data source: Swissmedic, *authorisation holder, **Refdata foundation, ***FOPH.